Search Results for: car t

Open-ended consultations on copyright limitations and exceptions for persons with print disabilities
Geneva, May 27, 2010

Mr. Chairman,

Yesterday, during the first round of the consultations, Brazil recalled the reasons why there is an urgent need for a treaty on Improved Access for Blind, Visually Impaired and other Reading Disabled Persons. As civil society representatives were not present yesterday, I will recall some of the main points Brazil holds dear in these discussions.

Continue Reading →

I was recently asked the following question:

Jamie
What is your view on the treatment of prize funds? By all standards it is treated as a radical off the wall proposal when in fact it is market based. Why is there so much resistance?

My response was as follows:

Continue Reading →

In a letter dated 4 May 2010, the Director General of the World Trade Organization (WTO), Pascal Lamy has responded to questions and concerns of the European Parliament regarding the Anti Counterfeiting Trade Agreement (ACTA). Continue Reading →

The Chapter FIVE (Institutional Arrangements) of ACTA is short. In less than 4 pages (pp 33-36) the negotiators “hereby establish” and “Oversight Steering Committee” (the OSC). Of course all of this chapter can be revisited later (see footnote 73) but let’s examine what is proposed now.

Continue Reading →

KEI has issued a new research note, Comments on ACTA Provisions on Injunctions and Damages, KEI Research Note 2010:1, dated April 6, 2010.

Continue Reading →

In looking at how enforcement norms are being changed in ACTA, it is helpful to review the enforcement chapter of NAFTA.

Article 1714: Enforcement of Intellectual Property Rights: General Provisions

Continue Reading →

KEI has access to yet undisclosed sections of the negotiating ACTA text. The text is organized in 6 chapters. The longest is Chapter 2 on “legal framework for enforcement of intellectual property rights.” The second longest is Chapter 5, on “Institutional Arrangements.” In ten pages of text, the ACTA negotiators have set out a plan to create a new institution to administer, implement and modify ACTA. Continue Reading →

Below are asks from the 2010 PhRMA submission to the USTR Special 301 list on the topic of drug pricing and reimbursement decisions, and described as ‘Market Access Barriers.’ In its assertions, PhRMA attack countries for government price negotiations, making use of reference pricing, the insufficient involvement of pharmaceutical companies in setting government pricing policies and the composition of drug formularies, among other things.

CHINA

Continue Reading →